Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/b Trial of CG-806 in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndromes

NCT04477291 is registered in ClinicalTrials.gov with Aptose Biosciences Inc. as lead sponsor.

NCT NCT04477291
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04477291 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/b Trial of CG-806 in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndromes
Lead sponsor
Aptose Biosciences Inc.
Phase
Phase 1
Overall status
Terminated
Start date
October 6, 2020
Completion date
April 15, 2024
Enrollment
45 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, myelodysplastic syndromes